Neurodegeneration and Neuroinflammation in Parkinson’s Disease: a Self-Sustained Loop

Animals; Gastrointestinal Microbiome; Humans; Inflammation; Neuroinflammatory Diseases; Neurons; Parkinson Disease; antiinflammatory agent; biological activity; cell function; cell interaction; cell junction; clinical feature; disease association; disease control; disease course; disorders of mitochondrial functions; DJ 1 gene; environmental factor; evidence based practice; GBA gene; gene; gene mutation; genetic association; glia cell; human; immune response; immune system; intercellular signaling; intestine flora; LRRK2 gene; nerve cell; nerve degeneration; nervous system inflammation; nonhuman; Parkin gene; Parkinson disease; pathophysiology; PINK1 gene; protein aggregation; Review; SNCA gene; animal; inflammation; intestine flora; metabolism

Résumé :

[en] Purpose of Review: Neuroinflammation plays a significant role in Parkinson’s disease (PD) etiology along with mitochondrial dysfunction and impaired proteostasis. In this context, mechanisms related to immune response can act as modifiers at different steps of the neurodegenerative process and justify the growing interest in anti-inflammatory agents as potential disease-modifying treatments in PD. The discovery of inherited gene mutations in PD has allowed researchers to develop cellular and animal models to study the mechanisms of the underlying biology, but the original cause of neuroinflammation in PD is still debated to date. Recent Findings: Cell autonomous alterations in neuronal cells, including mitochondrial damage and protein aggregation, could play a role, but recent findings also highlighted the importance of intercellular communication at both local and systemic level. This has given rise to debate about the role of non-neuronal cells in PD and reignited intense research into the gut-brain axis and other non-neuronal interactions in the development of the disease. Whatever the original trigger of neuroinflammation in PD, what appears quite clear is that the aberrant activation of glial cells and other components of the immune system creates a vicious circle in which neurodegeneration and neuroinflammation nourish each other. Summary: In this review, we will provide an up-to-date summary of the main cellular alterations underlying neuroinflammation in PD, including those induced by environmental factors (e.g. the gut microbiome) and those related to the genetic background of affected patients. Starting from the lesson provided by familial forms of PD, we will discuss pathophysiological mechanisms linked to inflammation that could also play a role in idiopathic forms. Finally, we will comment on the potential clinical translatability of immunobiomarkers identified in PD patient cohorts and provide an update on current therapeutic strategies aimed at overcoming or preventing inflammation in PD. © 2022, The Author(s).

Disciplines :

Biochimie, biophysique & biologie moléculaire

Auteur, co-auteur :

ARENA, Giuseppe ; University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Translational Neuroscience

Sharma, K.

AGYEAH, Gideon ; University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Molecular and Functional Neurobiology

KRÜGER, Rejko ; University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Translational Neuroscience

GRÜNEWALD, Anne ; University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Molecular and Functional Neurobiology

Fitzgerald, J. C.

Co-auteurs externes :

yes

Titre :

Neurodegeneration and Neuroinflammation in Parkinson’s Disease: a Self-Sustained Loop

Date de publication/diffusion :

2022

Titre du périodique :

Current Neurology and Neuroscience Reports

ISSN :

1528-4042

Maison d'édition :

Springer

Volume/Tome :

Fascicule/Saison :

Pagination :

427 – 440

Peer reviewed :

Peer reviewed

URL complémentaire :

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131565269&doi=10.1007%2fs11910-022-01207-5&partnerID=40&md5=68bca7cd008f2e7307f48413aee5e1de

Projet FnR :

FNR15850547 - Pink1-related Molecular Mechanisms To Dissect The Connection Between Type 2 Diabetes And Insulin Resistance In Parkinson'S Disease, 2021 (01/01/2022-31/08/2024) - Giuseppe Arena

Commentaire :

Cited by: 0; All Open Access, Green Open Access, Hybrid Gold Open Access

Disponible sur ORBilu :

depuis le 25 septembre 2022

Statistiques

Nombre de vues

240 (dont 2 Unilu)

Nombre de téléchargements

73 (dont 3 Unilu)

Voir plus de statistiques

citations Scopus^®

citations Scopus^®
sans auto-citations

OpenCitations

citations OpenAlex

citations WoS^™

Bibliographie

Spillantini MG, Schmidt ML, Lee VM-Y, Trojanowski JQ, Jakes R, Goedert M. α-Synuclein in Lewy bodies. Nature. 1997;388:839–40.
Moors TE, Maat CA, Niedieker D, et al. The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson’s disease brain as revealed by multicolor STED microscopy. Acta Neuropathol. 2021;142:423–48.
Rektor I, Goldemund D, Sheardová K, Rektorová I, Michálková Z, Dufek M. Vascular pathology in patients with idiopathic Parkinson’s disease. Parkinsonism & Related Disorders. 2009;15:24–9.
Jellinger KA. Prevalence of cerebrovascular lesions in Parkinson’s disease. A postmortem study. Acta Neuropathol. 2003;105:415–9.
Kam T-I, Hinkle JT, Dawson TM, Dawson VL. Microglia and astrocyte dysfunction in Parkinson’s disease. Neurobiology of Disease. 2020;144:105028 Comprehensive review discussing the implication of glial cells in PD pathogenesis, with a particular focus on monogenic forms.
Braak H, Tredici KD, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197–211.
Fang E, Fartaria MJ, Ann CN, et al. Clinical correlates of white matter lesions in Parkinson’s disease using automated multi-modal segmentation measures. J Neurol Sci. 2021;427:117518.
Zhang X, Svn Z, Liv M, Yang Y, Zeng R, Huang Q, Sun Q. Association between irritable bowel syndrome and risk of Parkinson’s disease: a systematic review and meta-analysis. Front Neurol. 2021;12:720958.
De Pablo-Fernandez E, Goldacre R, Pakpoor J, Noyce AJ, Warner TT. Association between diabetes and subsequent Parkinson disease: a record-linkage cohort study. Neurology. 2018;91:e139–42.
Liu G, Bao X, Jiang Y, et al. Identifying the association between Alzheimer’s disease and Parkinson’s disease using genome-wide association studies and protein-protein interaction network. Mol Neurobiol. 2015;52:1629–36.
Dorsey ER, Bloem BR. The Parkinson pandemic—a call to action. JAMA Neurol. 2018;75:9.
Walker KA. Inflammation and neurodegeneration: chronicity matters. Aging. 2018;11:3–4.
Kwon HS, Koh S-H. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener. 2020;9:42.
Chatterjee K, Roy A, Banerjee R, Choudhury S, Mondal B, Halder S, Basu P, Shubham S, Dey S, Kumar H. Inflammasome and α-synuclein in Parkinson’s disease: a cross-sectional study. Journal of Neuroimmunology. 2020;338:577089.
Puentes LN, Lengyel-Zhand Z, Lee JY, Hsieh C-J, Schneider ME, Edwards KJ, Luk KC, Lee VM-Y, Trojanowski JQ, Mach RH. Poly (ADP-ribose) interacts with phosphorylated α-synuclein in post mortem PD samples. Front Aging Neurosci. 2021;13:704041.
Ulhaq ZS, Garcia CP. Inflammation-related gene polymorphisms associated with Parkinson’s disease: an updated meta-analysis. Egypt J Med Hum Genet. 2020;21:14.
Wang J, Liu Y, Liu Y, Zhu K, Xie A. The association between TLR3 rs3775290 polymorphism and sporadic Parkinson’s disease in Chinese Han population. Neuroscience Letters. 2020;728:135005.
Missiroli S, Genovese I, Perrone M, Vezzani B, Vitto VAM, Giorgi C. The role of mitochondria in inflammation: from cancer to neurodegenerative disorders. JCM. 2020;9:740.
de Oliveira LG, de Angelo YS, Iglesias AH, JPS P. Unraveling the link between mitochondrial dynamics and neuroinflammation. Front Immunol. 2021;12:624919.
Kannarkat GT, Boss JM, Tansey MG. The role of innate and adaptive immunity in Parkinson’s disease. J Parkinson’s Disease. 2013;3:493–514.
MacMahon Copas AN, McComish SF, Fletcher JM, Caldwell MA. The pathogenesis of Parkinson’s disease: a complex interplay between astrocytes, microglia, and T lymphocytes? Front Neurol. 2021;12:666737.
Chitnis T, Weiner HL. CNS inflammation and neurodegeneration. J Clin Investig. 2017;127:3577–87.
Greenhalgh AD, David S, Bennett FC. Immune cell regulation of glia during CNS injury and disease. Nat Rev Neurosci. 2020;21:139–52.
Borsche M, König IR, Delcambre S, et al. Mitochondrial damage-associated inflammation highlights biomarkers in PRKN/PINK1 parkinsonism. Brain. 2020;143:3041–51 This study reported increased levels of inflammatory biomarkers (IL-6, ccf-mtDNA) in the serum of PD patients carrying homozygous mutations in PINK1 and Parkin, suggesting a causal link between impaired mitophagy and neuroinflammation in PD.
Harms AS, Ferreira SA, Romero-Ramos M. Periphery and brain, innate and adaptive immunity in Parkinson’s disease. Acta Neuropathol. 2021;141:527–45.
Roy Sarkar S, Banerjee S. Gut microbiota in neurodegenerative disorders. J Neuroimmunol. 2019;328:98–104.
Matheoud D, Cannon T, Voisin A, et al. Intestinal infection triggers Parkinson’s disease-like symptoms in Pink1−/− mice. Nature. 2019;571:565–9 This study demonstrated that bacterial infection in the gut of PINK1 knockout mice is able to trigger autoimmune mechanisms that lead to neuroinflammation and human-like L-DOPA responsive parkinsonism. Altogether, these findings highlight the importance of the gut-brain axis in PD pathogenesis, with intestinal infection acting as a primary event.
Kim S, Kwon S-H, Kam T-I, et al. Transneuronal propagation of pathologic α-synuclein from the gut to the brain models Parkinson’s disease. Neuron. 2019;103:627–641.e7.
Van Den Berge N, Ferreira N, Gram H, et al. Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats. Acta Neuropathol. 2019;138:535–50.
Fasano A, Visanji NP, Liu LWC, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2015;14:625–39.
Wallen ZD, Appah M, Dean MN, Sesler CL, Factor SA, Molho E, Zabetian CP, Standaert DG, Payami H. Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens. npj Parkinsons Dis. 2020;6:11.
Sharon G, Sampson TR, Geschwind DH, Mazmanian SK. The central nervous system and the gut microbiome. Cell. 2016;167:915–32.
Zhu S, Jiang Y, Xu K, Cui M, Ye W, Zhao G, Jin L, Chen X. The progress of gut microbiome research related to brain disorders. J Neuroinflammation. 2020;17:25.
Semin I, Ninnemann J, Bondareva M, Gimaev I, Kruglov AA. Interplay between microbiota, toll-like receptors and cytokines for the maintenance of epithelial barrier integrity. Front Med. 2021;8:644333.
Galea I. The blood–brain barrier in systemic infection and inflammation. Cell Mol Immunol. 2021;18:2489–501.
Wang C, Lau CY, Ma F, Zheng C. Genome-wide screen identifies curli amyloid fibril as a bacterial component promoting host neurodegeneration. Proc Natl Acad Sci USA. 2021;118:e2106504118.
Kaur H, Bose C, Mande SS. Tryptophan metabolism by gut microbiome and gut-brain-axis: an in silico analysis. Front Neurosci. 2019;13:1365.
Silva YP, Bernardi A, Frozza RL. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front Endocrinol. 2020;11:25.
Luu M, Pautz S, Kohl V, et al. The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes. Nat Commun. 2019;10:760.
Huang Y, Liao J, Liu X, Zhong Y, Cai X, Long L. Review: The role of intestinal dysbiosis in Parkinson’s disease. Front Cell Infect Microbiol. 2021;11:615075.
Baldini F, Hertel J, Sandt E, et al. Parkinson’s disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions. BMC Biol. 2020;18:62.
Song Y, Gong T, Xiang Y, Mikkelsen M, Wang G, Edden RAE. Single-dose L-dopa increases upper brainstem GABA in Parkinson’s disease: a preliminary study. J Neurol Sci. 2021;422:117309.
Błaszczyk JW. Parkinson’s disease and neurodegeneration: GABA-collapse hypothesis. Front Neurosci. 2016. 10.3389/fnins.2016.00269.
Scheperjans F, Aho V, Pereira PAB, et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord. 2015;30:350–8.
Li W, Wu X, Hu X, Wang T, Liang S, Duan Y, Jin F, Qin B. Structural changes of gut microbiota in Parkinson’s disease and its correlation with clinical features. Sci China Life Sci. 2017;60:1223–33.
Lolekha P, Sriphanom T, Vilaichone R-K. Helicobacter pylori eradication improves motor fluctuations in advanced Parkinson’s disease patients: a prospective cohort study (HP-PD trial). PLoS ONE. 2021;16:e0251042.
Ho MS. Microglia in Parkinson’s Disease. In: Verkhratsky A, Ho MS, Zorec R, Parpura V, editors. Neuroglia in neurodegenerative diseases. Singapore: Springer Singapore; 2019. p. 335–53.
McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology. 1988;38:1285–5.
Subbarayan MS, Hudson C, Moss LD, Nash KR, Bickford PC. T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an α-synuclein rat model of Parkinson’s disease. J Neuroinflammation. 2020;17:242.
Hoban DB, Connaughton E, Connaughton C, Hogan G, Thornton C, Mulcahy P, Moloney TC, Dowd E. Further characterisation of the LPS model of Parkinson’s disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat. Brain, Behavior, and Immunity. 2013;27:91–100.
Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Disease. 2006;21:404–12.
Badanjak K, Fixemer S, Smajić S, Skupin A, Grünewald A. The contribution of microglia to neuroinflammation in Parkinson’s disease. IJMS. 2021;22:4676.
Uriarte Huarte O, Kyriakis D, Heurtaux T, Pires-Afonso Y, Grzyb K, Halder R, Buttini M, Skupin A, Mittelbronn M, Michelucci A. Single-cell transcriptomics and in situ morphological analyses reveal microglia heterogeneity across the nigrostriatal pathway. Front Immunol. 2021;12:639613.
Lang C, Campbell KR, Ryan BJ, et al. Single-cell sequencing of iPSC-dopamine neurons reconstructs disease progression and identifies HDAC4 as a regulator of Parkinson cell phenotypes. Cell Stem Cell. 2019;24:93–106.e6.
Smajić S, Prada-Medina CA, Landoulsi Z, et al (2021) Single-cell sequencing of human midbrain reveals glial activation and a Parkinson-specific neuronal state. Brain awab 446. By means of single-nuclei RNA sequencing, the authors identified a significant upregulation of glial cells in postmortem midbrain tissues from idiopathic PD patients. Disease trajectory analyses identified stress related to accumulation of misfolded proteins as a major trigger of the observed pro-inflammatory phenotype.
Tran J, Anastacio H, Bardy C. Genetic predispositions of Parkinson’s disease revealed in patient-derived brain cells. npj Parkinsons Dis. 2020;6:8.
Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18:1091–102.
Day JO, Mullin S. The genetics of Parkinson’s disease and implications for clinical practice. Genes. 2021;12:1006.
Burré J. The synaptic function of α-synuclein. JPD. 2015;5:699–713.
Lema Tomé CM, Tyson T, Rey NL, Grathwohl S, Britschgi M, Brundin P. Inflammation and α-synuclein’s prion-like behavior in Parkinson’s disease—is there a link? Mol Neurobiol. 2013;47:561–74.
Croisier E, Moran LB, Dexter DT, Pearce RK, Graeber MB. Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflammation. 2005;2:14.
Zhang W, Wang T, Pei Z, et al. Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB j. 2005;19:533–42.
Thomas MP, Chartrand K, Reynolds A, Vitvitsky V, Banerjee R, Gendelman HE. Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson’s disease. J Neurochem. 2007;100:503–19.
Reynolds AD, Glanzer JG, Kadiu I, et al. Nitrated alpha-synuclein-activated microglial profiling for Parkinson’s disease: Synuclein-induced microglia activation. J Neurochem. 2008;104:1504–25.
Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff HJ. Synuclein activates microglia in a model of Parkinson’s disease. Neurobiol Aging. 2008;29:1690–701.
Theodore S, Cao S, McLean PJ, Standaert DG. Targeted overexpression of human α-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol. 2008;67:1149–58.
Hoenen C, Gustin A, Birck C, Kirchmeyer M, Beaume N, Felten P, Grandbarbe L, Heuschling P, Heurtaux T. Alpha-synuclein proteins promote pro-inflammatory cascades in microglia: stronger effects of the A53T mutant. PLoS ONE. 2016;11:e0162717.
Codolo G, Plotegher N, Pozzobon T, Brucale M, Tessari I, Bubacco L, de Bernard M. Triggering of inflammasome by aggregated α–synuclein, an inflammatory response in synucleinopathies. PLoS ONE. 2013;8:e55375.
Gordon R, Albornoz EA, Christie DC, et al. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med. 2018;10:eaah4066.
Pike AF, Varanita T, Herrebout MAC, Plug BC, Kole J, Musters RJP, Teunissen CE, Hoozemans JJM, Bubacco L, Veerhuis R. α-Synuclein evokes NLRP3 inflammasome-mediated IL-1β secretion from primary human microglia. Glia. 2021;69:1413–28 This study demonstrated that exposure of primary human microglia to α-synuclein fibrils activates the NLRP3 inflammasome, suggesting that this pathway can play a crucial role in PD pathogenesis.
Piancone F, Saresella M, La Rosa F, Marventano I, Meloni M, Navarro J, Clerici M. Inflammatory responses to monomeric and aggregated α-synuclein in peripheral blood of Parkinson disease patients. Front Neurosci. 2021;15:639646.
Niu M, Li Y, Li G, Zhou L, Luo N, Yao M, Kang W, Liu J. A longitudinal study on α-synuclein in plasma neuronal exosomes as a biomarker for Parkinson’s disease development and progression. Eur J Neurol. 2020;27:967–74.
Jiang C, Hopfner F, Katsikoudi A, et al. Serum neuronal exosomes predict and differentiate Parkinson’s disease from atypical parkinsonism. J Neurol Neurosurg Psychiat. 2020;91:720–9.
Benskey MJ, Sellnow RC, Sandoval IM, Sortwell CE, Lipton JW, Manfredsson FP. Silencing alpha synuclein in mature nigral neurons results in rapid neuroinflammation and subsequent toxicity. Front Mol Neurosci. 2018;11:36.
Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology. Neuron. 2004;44:601–7.
Paisán-Ruíz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron. 2004;44:595–600.
Thévenet J, Pescini Gobert R, Hooft van Huijsduijnen R, Wiessner C, Sagot YJ. Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS ONE. 2011;6:e21519.
Gillardon F, Schmid R, Draheim H. Parkinson’s disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience. 2012;208:41–8.
Li T, Ning B, Kong L, Dai B, He X, Thomas JM, Sawa A, Ross CA, Smith WW. A LRRK2 GTP binding inhibitor, 68, reduces LPS-induced signaling events and TNF-α release in human lymphoblasts. Cells. 2021;10:480 Findings from this study indicate that LRRK2 is implicated in pro-inflammatory pathways in human lymphoblasts, whereas LRRK2 pharmacological inhibition reduces inflammation.
Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science. 2004;304:1158–60.
Zheng X, Hunter T. Pink1, the first ubiquitin kinase. EMBO J. 2014;33:1621–3.
Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605–8.
Lazarou M, Sliter DA, Kane LA, Sarraf SA, Wang C, Burman JL, Sideris DP, Fogel AI, Youle RJ. The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy. Nature. 2015;524:309–14.
Henn IH, Bouman L, Schlehe JS, et al. Parkin mediates neuroprotection through activation of I B kinase/nuclear factor-B signaling. J Neurosci. 2007;27:1868–78.
Sun L, Shen R, Agnihotri SK, Chen Y, Huang Z, Büeler H. Lack of PINK1 alters glia innate immune responses and enhances inflammation-induced, nitric oxide-mediated neuron death. Sci Rep. 2018;8:383.
Fedele G, Loh S, Celardo I, Lehmann S, Costa A, Martins LM (2020) Gut-brain axis neurodegeneration in a Drosophila model of Parkinson’s disease is linked to mitochondrial dysfunction. 10.21203/rs.3.rs-100637/v1
Kim J, Byun J-W, Choi I, Kim B, Jeong H-K, Jou I, Joe E. PINK1 deficiency enhances inflammatory cytokine release from acutely prepared brain slices. Exp Neurobiol. 2013;22:38–44.
Akundi RS, Huang Z, Eason J, Pandya JD, Zhi L, Cass WA, Sullivan PG, Büeler H. Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice. PLoS ONE. 2011;6:e16038.
Zhou J, Yang R, Zhang Z, Liu Q, Zhang Y, Wang Q, Yuan H. Mitochondrial protein PINK1 positively regulates RLR signaling. Front Immunol. 2019;10:1069.
Chung J-Y, Park HR, Lee S-J, et al. Elevated TRAF2/6 expression in Parkinson’s disease is caused by the loss of Parkin E3 ligase activity. Lab Invest. 2013;93:663–76.
Frank-Cannon TC, Tran T, Ruhn KA, et al. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. Journal of Neuroscience. 2008;28:10825–34.
Yunfu W, Guangjian L, Ping Z, et al. PINK1 and its familial Parkinson’s disease-associated mutation regulate brain vascular endothelial inflammation. J Mol Neurosci. 2014;53:109–16.
Matheoud D, Sugiura A, Bellemare-Pelletier A, et al. Parkinson’s disease-related proteins PINK1 and Parkin repress mitochondrial antigen presentation. Cell. 2016;166:314–27.
Torres-Odio S, Key J, Hoepken H-H, et al. Progression of pathology in PINK1-deficient mouse brain from splicing via ubiquitination, ER stress, and mitophagy changes to neuroinflammation. J Neuroinflammation. 2017;14:154.
Decout A, Katz JD, Venkatraman S, Ablasser A. The cGAS–STING pathway as a therapeutic target in inflammatory diseases. Nat Rev Immunol. 2021;21:548–69 Very recent and comprehensive review article discussing the emerging role of the cGAS–STING signalling pathway in inflammation and neurodegeneration.
Sliter DA, Martinez J, Hao L, et al. Parkin and PINK1 mitigate STING-induced inflammation. Nature. 2018;561:258–62.
Lee JJ, Andreazza S, Whitworth AJ. The STING pathway does not contribute to behavioural or mitochondrial phenotypes in Drosophila Pink1/parkin or mtDNA mutator models. Sci Rep. 2020;10:2693.
Antico O, Ordureau A, Stevens M, et al. Global ubiquitylation analysis of mitochondria in primary neurons identifies endogenous Parkin targets following activation of PINK1. Sci Adv. 2021;7:eabj0722.
McWilliams TG, Prescott AR, Montava-Garriga L, Ball G, Singh F, Barini E, Muqit MMK, Brooks SP, Ganley IG. Basal mitophagy occurs independently of PINK1 in mouse tissues of high metabolic demand. Cell Metabolism. 2018;27:439–449.e5.
Allen GFG, Toth R, James J, Ganley IG. Loss of iron triggers PINK1/Parkin-independent mitophagy. EMBO Rep. 2013;14:1127–35.
Lee JJ, Sanchez-Martinez A, Zarate AM, Benincá C, Mayor U, Clague MJ, Whitworth AJ. Basal mitophagy is widespread in Drosophila but minimally affected by loss of Pink1 or parkin. J Cell Biol. 2018;217:1613–22.
Manzanillo PS, Ayres JS, Watson RO, Collins AC, Souza G, Rae CS, Schneider DS, Nakamura K, Shiloh MU, Cox JS. The ubiquitin ligase parkin mediates resistance to intracellular pathogens. Nature. 2013;501:512–6.
Li J, Ma C, Long F, et al. Parkin impairs antiviral immunity by suppressing the mitochondrial reactive oxygen species-Nlrp3 Axis and antiviral inflammation. iScience. 2019;16:468–84.
Mouton-Liger F, Jacoupy M, Corvol J-C, Corti O. PINK1/Parkin-dependent mitochondrial surveillance: from pleiotropy to Parkinson’s disease. Front Mol Neurosci. 2017;10:120.
Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299:256–9.
Ariga H, Takahashi-Niki K, Kato I, Maita H, Niki T, Iguchi-Ariga SMM. Neuroprotective function of DJ-1 in Parkinson’s disease. Oxidative Med Cell Longevity. 2013;2013:1–9.
Frøyset AK, Edson AJ, Gharbi N, et al. Astroglial DJ-1 over-expression up-regulates proteins involved in redox regulation and is neuroprotective in vivo. Redox Biol. 2018;16:237–47.
Edson AJ, Hushagen HA, Frøyset AK, Elda I, Khan EA, Di Stefano A, Fladmark KE. Dysregulation in the brain protein profile of zebrafish lacking the Parkinson’s disease-related protein DJ-1. Mol Neurobiol. 2019;56:8306–22.
Singh Y, Trautwein C, Dhariwal A, et al. DJ-1 (Park7) affects the gut microbiome, metabolites and the development of innate lymphoid cells (ILCs). Sci Rep. 2020;10:16131 This study provides evidence that DJ-1 is implicated in the regulation of mouse gut microbiome. Indeed, DJ-1 knockout mice display signs of intestinal inflammation and altered metabolic profile, likely due to higher abundance of specific gut microbial species. Notably, expression of PD-related inflammatory genes was increased in the midbrain of these mice, suggesting that bacterial metabolites and inflammatory mediators could trigger neuroinflammation and play a role in PD pathogenesis.
Lin Z, Chen C, Yang D, Ding J, Wang G, Ren H. DJ-1 inhibits microglial activation and protects dopaminergic neurons in vitro and in vivo through interacting with microglial p65. Cell Death Dis. 2021;12:715.
Zhao M, Wang B, Zhang C, Su Z, Guo B, Zhao Y, Zheng R. The DJ1-Nrf2-STING axis mediates the neuroprotective effects of Withaferin A in Parkinson’s disease. Cell Death Differ. 2021;28:2517–35.
Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med. 2009;361:1651–61.
Balestrino R, Tunesi S, Tesei S, Lopiano L, Zecchinelli AL, Goldwurm S. Penetrance of glucocerebrosidase (GBA) mutations in Parkinson’s disease: a kin cohort study. Mov Disord. 2020;35:2111–4.
Velayati A, Yu WH, Sidransky E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep. 2010;10:190–8.
Mazzulli JR, Xu Y-H, Sun Y, Knight AL, McLean PJ, Caldwell GA, Sidransky E, Grabowski GA, Krainc D. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146:37–52.
Sardi SP, Clarke J, Kinnecom C, et al. CNS expression of glucocerebrosidase corrects -synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci. 2011;108:12101–6.
Polinski NK, Martinez TN, Gorodinsky A, et al. Decreased glucocerebrosidase activity and substrate accumulation of glycosphingolipids in a novel GBA1 D409V knock-in mouse model. PLoS ONE. 2021;16:e0252325.
Fredriksen K, Aivazidis S, Sharma K, Burbidge KJ, Pitcairn C, Zunke F, Gelyana E, Mazzulli JR. Pathological α-syn aggregation is mediated by glycosphingolipid chain length and the physiological state of α-syn in vivo. Proc Natl Acad Sci USA. 2021;118:e2108489118.
Gustot A, Gallea JI, Sarroukh R, Celej MS, Ruysschaert J-M, Raussens V. Amyloid fibrils are the molecular trigger of inflammation in Parkinson’s disease. Biochem J. 2015;471:323–33.
Dutta D, Jana M, Majumder M, Mondal S, Roy A, Pahan K. Selective targeting of the TLR2/MyD88/NF-κB pathway reduces α-synuclein spreading in vitro and in vivo. Nat Commun. 2021;12:5382.
Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, Stefanis L, Vekrellis K. Cell-produced-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci. 2010;30:6838–51.
Flavin WP, Bousset L, Green ZC, Chu Y, Skarpathiotis S, Chaney MJ, Kordower JH, Melki R, Campbell EM. Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins. Acta Neuropathol. 2017;134:629–53.
Freundt EC, Maynard N, Clancy EK, Roy S, Bousset L, Sourigues Y, Covert M, Melki R, Kirkegaard K, Brahic M. Neuron-to-neuron transmission of α-synuclein fibrils through axonal transport. Ann Neurol. 2012;72:517–24.
Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, Mann DMA, Hasegawa M. Prion-like spreading of pathological α-synuclein in brain. Brain. 2013;136:1128–38.
Scheiblich H, Dansokho C, Mercan D, et al. Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes. Cell. 2021;184:5089–5106.e21 In this paper, the authors demonstrated that microglia make use of tunneling nanotubes to dilute the burden of excessive α-synuclein accumulation and attenuate inflammation. At the same time, healthy microglia are able to donate mitochondria to α-synuclein overloaded cells to improve their bioenergetic efficiency.
Rostami J, Mothes T, Kolahdouzan M, et al. Crosstalk between astrocytes and microglia results in increased degradation of α-synuclein and amyloid-β aggregates. J Neuroinflammation. 2021;18:124.
Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255–89.
Mustapic M, Eitan E, Werner JK, Berkowitz ST, Lazaropoulos MP, Tran J, Goetzl EJ, Kapogiannis D. Plasma extracellular vesicles enriched for neuronal origin: a potential window into brain pathologic processes. Front Neurosci. 2017;11:278.
Gui Y, Liu H, Zhang L, Lv W, Hu X. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget. 2015;6:37043–53.
Hong Z, Shi M, Chung KA, et al. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain. 2010;133:713–26.
Hong Z, Tian C, Stewart T, et al. Development of a sensitive diagnostic assay for Parkinson disease quantifying α-synuclein–containing extracellular vesicles. Neurology. 2021;96:e2332–45.
Picca A, Guerra F, Calvani R, et al. Mitochondrial signatures in circulating extracellular vesicles of older adults with Parkinson’s disease: results from the EXosomes in PArkiNson’s Disease (EXPAND) Study. JCM. 2020;9:504.
De Gaetano A, Solodka K, Zanini G, Selleri V, Mattioli AV, Nasi M, Pinti M. Molecular mechanisms of mtDNA-mediated inflammation. Cells. 2021;10:2898.
Gambardella S, Limanaqi F, Ferese R, Biagioni F, Campopiano R, Centonze D, Fornai F. ccf-mtDNA as a potential link between the brain and immune system in neuro-immunological disorders. Front Immunol. 2019;10:1064.
Blum-Degena D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer’s and de novo Parkinson’s disease patients. Neuroscie Lett. 1995;202:17–20.
Müller T, Blum-Degen D, Przuntek H, Kuhn W. Short communication interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson’s disease. Acta Neurologica Scandinavica. 2009;98:142–4.
McGeer PL, Yasojima K, McGeer EG. Association of interleukin-1β polymorphisms with idiopathic Parkinson’s disease. Neurosci Lett. 2002;326:67–9.
McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson’s disease. Parkinsonism & Related Disorders. 2004;10:S3–7.
Wang X, Chi J, Huang D, Ding L, Zhao X, Jiang L, Yu Y, Gao F. α-synuclein promotes progression of Parkinson’s disease by upregulating autophagy signaling pathway to activate NLRP3 inflammasome. Exp Ther Med. 2019. 10.3892/etm.2019.8297.
Fan Z, Pan Y-T, Zhang Z-Y, Yang H, Yu S-Y, Zheng Y, Ma J-H, Wang X-M. Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson’s disease. J Neuroinflammation. 2020;17:11.
Solini A, Rossi C, Santini E, Giuntini M, Raggi F, Parolini F, Biancalana E, Del Prete E, Bonuccelli U, Ceravolo R. P2X7 receptor/NLRP3 inflammasome complex and α-synuclein in peripheral blood mononuclear cells: a prospective study in neo-diagnosed, treatment-naïve Parkinson’s disease. Eur J Neurol. 2021;28:2648–56.
Deleidi M, JÃggle M, Rubino G. Immune aging, dysmetabolism, and inflammation in neurological diseases. Front Neurosci. 2015. 10.3389/fnins.2015.00172.
Sulzer D, Alcalay RN, Garretti F, et al. T cells from patients with Parkinson’s disease recognize α-synuclein peptides. Nature. 2017;546:656–61.
Ding X-B, Wang X-X, Xia D-H, et al. Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson’s disease. Nat Med. 2021;27:411–8.
Zou W, Pu T, Feng W, Lu M, Zheng Y, Du R, Xiao M, Hu G. Blocking meningeal lymphatic drainage aggravates Parkinson’s disease-like pathology in mice overexpressing mutated α-synuclein. Transl Neurodegener. 2019;8:7.
Chahine LM, Qiang J, Ashbridge E, et al. Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. JAMA Neurol. 2013;70:852.
Miliukhina IV, Usenko TS, Senkevich KA, Nikolaev MA, Timofeeva AA, Agapova EA, Semenov AV, Lubimova NE, Totolyan AA, Pchelina SN. Plasma cytokines profile in patients with Parkinson’s disease associated with mutations in GBA gene. Bull Exp Biol Med. 2020;168:423–6.
Mullin S, Stokholm MG, Hughes D, Mehta A, Parbo P, Hinz R, Pavese N, Brooks DJ, Schapira AHV. Brain microglial activation increased in glucocerebrosidase (GBA) mutation carriers without Parkinson’s disease. Mov Disord. 2021;36:774–9.
Galper J, Balwani M, Fahn S, Waters C, Krohn L, Gan-Or Z, Dzamko N, Alcalay RN. Cytokines and Gaucher biomarkers in glucocerebrosidase carriers with and without Parkinson disease. Mov Disord. 2021;36:1451–5.
Dzamko N, Rowe DB, Halliday GM. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers: inflammatory biomarkers for Parkinson’s disease. Mov Disord. 2016;31:889–97.
Brockmann K, Apel A, Schulte C, et al. Inflammatory profile in LRRK2-associated prodromal and clinical PD. J Neuroinflammation. 2016;13:122.
Cook DA, Kannarkat GT, Cintron AF, et al (2017) LRRK2 levels in immune cells are increased in Parkinson’s disease. npj Parkinson’s Disease 3:11
Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology. 2010;74:995–1002.
Hui KY, Fernandez-Hernandez H, Hu J, et al. Functional variants in the LRRK2 gene confer shared effects on risk for Crohn’s disease and Parkinson’s disease. Sci Transl Med. 2018;10:eaai7795.
San Luciano M, Tanner CM, Meng C, et al. Nonsteroidal anti-inflammatory use and LRRK2 Parkinson’s disease penetrance. Mov Disord. 2020;35:1755–64.
Brown EG, Goldman SM. Modulation of the microbiome in Parkinson’s disease: diet, drug, stool transplant, and beyond. Neurotherapeutics. 2020;17:1406–17.
Sampson TR, Debelius JW, Thron T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell. 2016;167:1469–1480.e12.
Pagano G, Boess FG, Taylor KI, et al. A phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease (PASADENA): rationale, design, and baseline data. Front Neurol. 2021;12:705407.
Wojewska DN, Kortholt A. LRRK2 targeting strategies as potential treatment of Parkinson’s disease. Biomolecules. 2021;11:1101.